‘Sugar Rush’ is a ‘perfect storm’ for hepatitis C drug coverage
When a doctor gives you a shot of an experimental hepatitis C treatment, you may not remember that the doctor was a drug company lobbyist who is still fighting to make sure you get the drug.That’s because the company’s new drug, SMAQ-A2, is being marketed as a treatment for hepatitis A. The drug has been…